Daily dose requirements removed from PBS listings for ezetimibe and ezetimibe with simvastatin (Ezetrol, Vytorin)Daily dose requirements removed from
PBS listings for ezetimibe and
ezetimibe with simvastatin (Ezetrol, Vytorin)

Published 2011-07-01 00:00:00

References


From 1 July 2011 prescribers will be permitted to prescribe ezetimibe or ezetimibe with simvastatin without regard to the dose of statin that is co-prescribed:1

  • a patient is now considered to have inadequate control after ≥ 3 months of treatment at a maximum tolerated dose of a statin. The requirement of a statin dose ≥ 40 mg daily has been removed.2
  • prescribers may now use their clinical judgment when reducing the dose of a statin in response to an adverse effect. The requirement to reduce the dose of a statin to < 20 mg daily has been removed.2

References

  1. Pharmaceutical Benefits Advisory Committee. Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in March 2011 relating to the listing of drugs on the Pharmaceutical Benefits Scheme. Canberra: Australian Government Department of Health and Ageing, 2011. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2011-03 (accessed 3 May 2011).
  2. Department of Health and Ageing. PBS for Health Professionals. Canberra, 2011. http://www.pbs.gov.au/ (accessed 9 May 2011).

RSS FeedRSS feed

Date published: 2011-07-01 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.